

# Synthesis and Anti-Microbial Activity of Pyrazolybiscoumarin

Karthikeyan Kandasamy, Ganesabaskaran Sivaprasad\* and Manimaran Muthusamy<sup>#</sup>

\*Department of Chemistry, University college of Engineering Tindivanam,  
Melpakkam – 604 001.

<sup>#</sup>Department of Botany, Presidency College, Chennai – 600 005.  
Tamil Nadu, India

e-mail: dr.g.sivaprasad@gmail.com

**Abstract—** By condensation reaction of substituted pyrazole aldehydes with 4-hydroxycoumarin a series of pyrazolybiscoumarin derivatives have been prepared. The prepared pyrazolybiscoumarin were evaluated for anti-microbial activities. The effect of pyrazolybiscoumarin on the growth of bacteria and fungi is revealed.

**Keywords;** pyrazolybiscoumarin, anti-microbial activity, agar dilution method.

## I. INTRODUCTION

Biscoumarin derivatives are widely used as anticoagulants, anti-inflammatories, HIV-1 integrase inhibition activators, rodenticides, and urease inhibitors [1–4]. Similarly pyrazoles possess anticonvulsant, antidepressant, antifungal, anti-inflammatory, antimicrobial, and PGE2 inhibitory properties [5–10]. This provoked us to fuse pyrazole with biscoumarin moieties. Protic acids, quarternary ammonium salts, silica based catalysts, nanoparticles, resins, heteropoly acids [11–23] and heterogeneous solid acid catalysts [24–28] were successfully employed in the preparation of biscoumarins.

## II. TYPICAL REACTION PROCEDURE FOR PYRAZOLYL BISCOUMARIN PREPARATION

The pyrazole aldehydes and pyrazolyl biscoumarins were prepared (Figure 1) using reported procedure [29]. The prepared products (TABLE I) were confirmed by <sup>1</sup>H NMR, <sup>13</sup>C NMR, FTIR and mass spectra.




Figure 1. Synthesis of pyrazole based biscoumarin

TABLE I. BISCOUMARINS OBTAINED BY THE REACTION OF 4-HYDROXY COUMARIN WITH SUBSTITUTED PYRAZOLE ALDHYDES OVER FETUD-1<sup>A</sup>

S.No.	Product	R1	R2	<sup>B</sup> Yield %
1	3a	H	H	85
2	3b	H	NO2	74
3	3c	p-CH3	H	88
4	3d	p-CH3	NO2	79
5	3e	p-Cl	H	80
6	3f	p-Cl	NO2	72

<sup>A</sup> Reaction conditions: Pyrazole aldehyde – 1 mmol, 4-hydroxy coumarin – 2 mmol, catalyst – 60 mg, Ethanol – 5 ml, reflux - 80 °C, 1 h.

<sup>B</sup> Isolated yield

**(3a)** 4-Hydroxy-3-((4-hydroxy-2-oxo-2H-chromen-3-yl)(1,3-diphenyl 1H-pyrazol-4-yl)methyl)-2H-chromen-2-one. Colourless solid; M.pt: 222°C; FTIR max (KBr): 3434, 3056, 2025, 1654, 1619, 1110, 906, 759, 694, 469 cm<sup>-1</sup>; <sup>1</sup>H NMR: 6.42 (1H, s), 6.98 (1H, t, J = 7–7.5), 7.08 (2H, t, J = 7–8), 7.25–7.30 (5H, m), 7.43–7.49 (4H, m), 7.55 (2H, t, J = 8), 7.81 (2H, d, J = 8), 7.87 (2H, d, J = 8.5), 8.35 (1H, s), 10.79 (2H, bs); <sup>13</sup>C NMR: 29.1, 104.6, 116.2, 117.9, 118.2, 120.1, 120.4, 124.1, 124.2, 126.2, 127.5, 127.8, 127.8, 128.2, 129.5, 129.9, 130.1, 130.5, 132.2, 134.0, 140.0, 151.4, 152.4, 164.6, 164.9; GC-MS m/z: 554 (M+); anal. calcd for C<sub>34</sub>H<sub>22</sub>N<sub>2</sub>O<sub>6</sub>: C, 73.64; H, 4.00; N, 5.05. Anal. found: C, 73.58; H, 3.89; N, 5.02.

**(3b)** 4-hydroxy-3-((4-hydroxy-2-oxo-2H-chromen-3-yl)(1-(4-nitrophenyl)-3-phenyl-1H-pyrazol-4-yl)methyl)-2H-chromen-2-one. Brown colour solid; M.pt: 233°C; <sup>1</sup>H NMR: 6.36 (1H, s), 6.79 (1H, t, J = 7–7.5), 6.86 (2H, t, J = 7.8), 7.15–7.7 (4H, m), 7.32–7.38 (4H, m), 7.47 (2H, t, J = 8), 7.79 (2H, t, J = 8), 7.82 (2H, d, J = 8.5), 8.08 (1H, s), 10.43 (2H, bs); <sup>13</sup>C NMR: 29.5, 104.8, 16.5, 118.2, 118.4, 120.4, 120.6, 124.4, 124.6, 125.4, 127.8, 128.0, 128.0, 129.1, 129.7, 130.7, 131.6, 131.7, 132.5, 134.3, 140.3, 151.7, 152.7, 164.8, 165.2; GC-MS m/z: 599 (M+); Anal. calcd for C<sub>34</sub>H<sub>21</sub>N<sub>3</sub>O<sub>8</sub>: C, 68.11; H, 3.53; N, 7.01. Anal. found: C, 68.03; H, 3.41; N, 6.98.

**(3c)** 4-hydroxy-3-((4-hydroxy-2-oxo-2H-chromen-3-yl)(1-phenyl-3-p-tolyl-1H-pyrazol-4-yl)methyl)-2H-chromen-2-one. Yellow colour solid; M.pt: 210 °C; FTIR max (KBr): 3436, 3045, 608, 1655, 1348, 1088, 920, 762 cm<sup>-1</sup>; <sup>1</sup>H NMR: 2.1 (3H, s), 6.33 (1H, s), 6.86 (2H, d, J = 8), 7.23 (5H, m), 7.31 (2H, d, J = 7.5), 7.44 (2H, t, J = 7.4), 7.50 (2H, t, J = 7.5), 7.78 (4H, d, J = 7.5), 8.21 (1H, s), 11 (2H, bs); <sup>13</sup>C NMR 21.1, 29.1, 91.0, 104.4, 116.0, 118.2, 118.4, 121.5, 123.7, 124.3, 125.9, 127.7, 128.1, 128.4, 129.8, 131.5, 131.7, 140.1, 152.6, 152.7, 164.8, 166.8; GC-MS m/z: 568 (M+); Anal. calcd for C<sub>35</sub>H<sub>24</sub>N<sub>2</sub>O<sub>6</sub>: C, 73.93; H, 4.25; N, 4.93. Anal. found: C, 73.84; H, 4.28; N, 4.59.

**(3d)** 4-hydroxy-3-((4-hydroxy-2-oxo-2H-chromen-3-yl)(1-(4-nitrophenyl)-3-p-tolyl-1H-pyrazol-4-yl)methyl)-2H-chromen-2-one. Brown colour solid; M.pt: 206°C; FTIR max (KBr): 3395, 3045, 2590, 1632, 1336, 1094, 952, 762, 520 cm<sup>-1</sup>; <sup>1</sup>H NMR: 2.09 (3H, s), 6.30 (1H, s), 6.88 (2H, d, J = 7.5), 7.20 (4H, m), 7.31 (2H, d, J = 8), 7.38 (2H, d, J = 8.5), 7.47 (2H, t, J = 8.5), 7.75 (2H, d, J = 8), 7.91 (2H, d, J = 8.5), 8.12 (1H, s), 10.69 (2H, bs); <sup>13</sup>C NMR: 21.1, 29.0, 91.5, 104.1, 115.9, 119.2, 119.5, 122.2, 123.4, 124.1, 122.4, 127.6, 128.1, 128.4, 130.2, 131.2, 131.4, 136.7, 152.6, 152.7, 164.6, 166.7; GC-MS m/z: 613 (M+); Anal. calcd for C<sub>35</sub>H<sub>23</sub>N<sub>3</sub>O<sub>8</sub>: C, 68.51; H, 3.78; N, 6.85. Anal. found: C, 68.39; H, 3.76; N, 6.54.

**(3e)** 3-((3-(4-chlorophenyl)-1-phenyl-1H-pyrazol-4-yl)(4-hydroxy-2-oxo-2H-chromen-3-yl)methyl)-4-hydroxy-2H-chromen-2-one. Light yellow colour solid; M.pt: 220°C; FTIR max (KBr): 3424, 3058, 2608, 1649, 1608, 1094, 910, 768, 680, 460 cm<sup>-1</sup>; <sup>1</sup>H NMR: 6.30 (1H, s), 7.10 (2H, d, J = 8), 7.22 (5H, m), 7.41 (2H, d, J = 7), 7.46 (2H, t, J = 7.4), 7.53 (2H, t, J = 7.5), 7.78 (2H, d, J = 8), 7.83 (2H, d, J = 7.5), 8.25 (1H, s), 10.87 (2H, bs); <sup>13</sup>C NMR: 29.2, 90.6, 103.6, 114.5, 118.3, 118.6, 121.3, 122.5, 123.3, 124.3, 126.8, 129.8, 127.2, 129.5, 129.9, 130.3, 135.7, 151.5, 151.7, 163.2, 165.6; GC-MS m/z: 588 (M+); Anal. calcd for C<sub>34</sub>H<sub>21</sub>ClN<sub>2</sub>O<sub>6</sub>: C, 69.33; H, 3.59; N, 4.76. Anal. found: C, 69.12; H, 3.48; N, 4.39.

**(3f)** 3-((3-(4-chlorophenyl)-1-(4-nitrophenyl)-1H-pyrazol-4-yl)(4-hydroxy-2-oxo-2H-chromen-3-yl)methyl)-4-hydroxy-2H-chromen-2-one. Brown colour solid; M.pt: 210°C; FTIR max (KBr): 3430, 3051, 2610, 1653, 1611, 1089, 930, 770, 685, 458 cm<sup>-1</sup>; <sup>1</sup>H NMR (500 MHz, DMSO-d<sub>6</sub>): 6.28 (1H, s), 6.99 (2H, d, J = 7.5), 7.15 (4H, m), 7.36 (2H, d, J = 8.5), 7.39 (2H, d, J = 8.5), 7.45 (2H, t, J = 8), 7.75 (2H, d, J = 8), 7.84 (2H, d, J = 8.5), 7.96 (1H, s), 10.55 (2H, bs); <sup>13</sup>C NMR (500 MHz, DMSO-d<sub>6</sub>): 29.5, 90.8, 103.8, 114.8, 118.5, 118.8, 121.6, 122.8, 123.6, 124.7, 126.1, 127.1, 127.4, 129.7, 130.7, 131.0, 136.0, 151.9, 151.9, 163.5, 165.9; GC-MS m/z: 633 (M+); Anal. calcd for C<sub>34</sub>H<sub>20</sub>ClN<sub>3</sub>O<sub>8</sub>: C, 64.41; H, 3.18; N, 6.63. Anal. found: C, 64.18; H, 2.98; N, 6.52.

In the present study, anti-bacterial activity against (human pathogenic bacteria) *Pseudomonas aeruginosa* and anti-fungal activity against (plant pathogenic fungi) *Rhizoctonia solani* was evaluated under in vitro condition using prepared pyrazolyl biscoumarin compounds. 10% DMSO is used as control for anti-microbial inhibition for the biological screening. Effect of pyrazolyl biscoumarin on the growth of human pathogen: The compounds inhibited the growth of human pathogens 12.2 % to 37.7% compared to control. (TABLE II).

Effect of pyrazolyl biscoumarin on the growth of plant pathogenic fungi: Anti-fungal activity against the plant pathogen was tested at a concentration of 1 mmol. The compounds inhibited *R. solani* 18.8% to 81.1% compared to control. (TABLE II).

TABLE II. EFFECT OF PYRAZOYL-BISCOUMARIN ON THE GROWTH OF HUMAN PATHOGEN AND ON MYCELIAL GROWTH OF PLANT PATHOGENIC FUNGI

Compound	Zone of inhibition (cm)	
	<i>P. aeruginosa</i>	<i>R. solani</i>
3a	2.2 (24.4)	4.9 (45.5)
3b	2.6 (28.8)	4.1 (54.4)
3c	1.1 (12.2)	7.3 (18.8)
3d	1.7 (18.8)	5.6 (37.7)

Compound	Zone of inhibition (cm)	Mycelial growth (cm)
	<i>P. aeruginosa</i>	<i>R. solani</i>
3e	2.7 (30.0)	1.9 (78.8)
3f	3.4 (37.7)	1.7 (81.1)

Figures in brackets are % inhibition as compared to control.

### III. MATERIALS AND METHODS FOR ANTI-MICROBIAL ACTIVITY

The human pathogen, *P. aeruginosa* were maintained on nutrient agar (NA) consisting of the following (g/L): beef extract 1.0; yeast extract 2.0; peptone 5.0; NaCl 5.0; agar 15.0; distilled H<sub>2</sub>O 1 L (pH 7.2) and the plant pathogen, *R. solani* were maintained on potato dextrose agar (PDA) that contained (g/L) potato 200.0; dextrose 20; agar 15.0; distilled H<sub>2</sub>O 1 L (pH 6.5) in slants or Petriplates at room temperature (28 ± 2 °C). Effect of pyrazolyl biscoumarins on the growth of human pathogenic bacteria: Agar diffusion method was used for the anti-bacterial activity of the compounds against human pathogen. Under aseptic conditions about 1 mL of inoculum of each test pathogen was added to the molten NA medium and then poured into sterile Petriplates. A 5 mm well was made in the centre of each plate using a sterile cork borer after solidification. 1 mmol concentration of each compound was prepared in 10% DMSO and filter sterilized using 0.25 µm filter paper. 50 µL solution of each compound was poured to each well and then plates were incubated at room temperature. Control used was sterile DMSO (10%). The appearance of inhibition zone around the well was observed after 48 hours. Effect of pyrazolyl biscoumarins on the growth of plant pathogenic fungi: Using poison plate technique, by measuring the mycelial growth of test fungi, the antifungal activity of each compound was tested. PDA amended with each compound was poured into 9 cm Petriplates and then inoculated with 5 mm mycelia discs of the test fungi. PDA containing Control used was 10% DMSO. For 6 days at room temperature the plates were incubated and the mycelial growth was measured.

### IV. CONCLUSION

The results obtained under this study clearly indicate that the series of pyrazolyl biscoumarins are active towards growth inhibition of pathogenic plant fungi and human pathogens. The compounds exhibited higher antifungal activity rather than antibacterial activity. Further studies pertaining to mode of action and MIC of the synthesized compounds are under study.

### REFERENCES

- [1] H. Hussain, J. Hussain, A. Al-Harrasi and K. Krohn, "The chemistry and biology of bicoumarins" Tetrahedron, 68, 2553–2578, 2012.
- [2] K. V. Sashidhara, M. Kumar, R. K. Modukuri, R. Sonkar, G. Bhatia, A. K. Khanna, S. Rai and R. Shukla, "Synthesis and anti-inflammatory activity of novel biscoumarin– chalcone hybrids" Bioorg. Med. Chem. Lett, 21, 4480–4484, 2011.
- [3] K. M. Khan, S. Iqbal, M. A. Lodhi, G. M. Maharvi, Z. Ullah, M. I. Choudhary, A.U. Rahman and S. Perveen, "Biscoumarin: new class of urease inhibitors; economical synthesis and activity" Bioorg. Med. Chem., 12, 1963–1968, 2004.
- [4] C.-X. Su, J.-F. Mouscadet, C.-C. Chiang, H.-J. Tsai and L.-Y. Hsu, "HIV-1 integrase inhibition of biscoumarin analogues" Chem. Pharm. Bull., 54, 682–686. 2006.
- [5] N. Gokhan-Kelekçi, S. Yabanoglu, E. Kupeli, U. Salgın, O. Ozgen, G. Uçar, E. Yesilada, E. Kendi, A. Yesilada and A. A. Bilgin, "A new therapeutic approach in Alzheimer disease: Some novel pyrazole derivatives as dual MAO-B inhibitors and antiinflammatory analgesics" Bioorg. Med. Chem., 15, 5775–5786, 2007.
- [6] A. Burguete, E. Pontiki, D. Hadjipavlou-Litina, R. Villar, E. Vicente, B. Solano, S. Ancizu, S. Perez-Silanes, I. Aldana and A. Monge, "Synthesis and anti-inflammatory/antioxidant activities of some new ring substituted 3-phenyl-1-(1,4-di-N-oxide quinoxalin-2-yl)-2-propen-1-one derivatives and of their 4,5-dihydro-(1H)-pyrazole analogues" Bioorg. Med. Chem. Lett., 17, 6439–6443, 2007.
- [7] M. Abdel-Aziz, G. El-Din A. Abuo-Rahma and A. A. Hassan, "Synthesis of novel pyrazole derivatives and evaluation of their antidepressant and anticonvulsant activities" Eur. J. Med. Chem., 44, 3480–3487, 2009.
- [8] F. F. Barsoum and A. S. Girgis, "Facile synthesis of bis(4,5-dihydro-1H-pyrazole-1-carboxamides) and their thio-analogues of potential PGE2 inhibitory properties" Eur. J. Med. Chem., 44, 2172– 2177, 2009.
- [9] G. Sivaprasad, P. T. Perumal, V. R. Prabavathy and N. Mathivanan., "Synthesis and anti-microbial activity of pyrazolylbisindoles— Promising anti-fungal compounds" Bioorg. Med. Chem. Lett., 16, 6302- 6305, 2006
- [10] M. A. Kira, M. O. Abdel-Rahman and K. Z. Gadalla, "The Vilsmeier- Haack Reaction – III cyclization of hydrazones to pyrazoles" Tetrahedron Lett., 10, 109–110, 1969
- [11] H. Mehrabi and H. Abusaidi, "Synthesis of biscoumarin and 3,4-dihydropyranoc[chromene derivatives catalysed by sodium dodecyl sulfate (SDS) in neat water" JICS, 7, 890–894, 2010
- [12] A. Davoodnia, "A highly efficient and fast method for the synthesis of biscoumarins using tetrabutylammonium hexatungstate [TBA]2[W6O19]" Bull. Korean Chem. Soc., 32, 4286–4290, 2011.
- [13] J. M. Khurana and S. Kumar, "Tetrabutylammonium bromide (TBAB): a neutral and efficient catalyst for the synthesis of biscoumarin and 3,4-dihydropyranoc[chromene derivatives in water and solvent-free conditions" Tetrahedron Lett., 50, 4125–4127, 2009

- [14] I. I. Manolov, "Aldehyde condensation products of 4- hydroxycoumarin and shiff bases" *Tetrahedron Lett.*, 39, 3041-3042, 1998.
- [15] C.-X. Su, J.-F. Mouscadet, C.-C. Chiang, H.-J. Tsai and L.-Y. Hsu, "Silica supported sodium hydrogen sulfate and Indion 190 resin: An efficient and heterogeneous catalysts for facile synthesis of bis-(4-hydroxycoumarin-3-yl) methanes" *Chem. Pharm. Bull.*, 54, 682-686, 2006.
- [16] K. Niknam and A. Jamali, "Silica-Bonded N-Propylpiperazine Sodium n-Propionate as Recyclable Basic Catalyst for Synthesis of 3,4-Dihydroprano[c]chromene Derivatives and Biscoumarins" *Chinese Journal of Catalysis*, 33,1840-1849, 2012.
- [17] J. M. Khurana and S. Kumar, "Ionic liquid: an efficient and recyclable medium for the synthesis of octahydroquinazolinone and biscoumarin derivatives", *Monatsh Chem* 141, 561-564, 2010.
- [18] M. M. Heravi, F. Nahavandi, S. Sadjadi, H. A. Oskooie and F. F. Bamoharram, "Efficient synthesis of bis-coumarins using silica-supported preyssler nanoparticles" *Synthetic Communications*, 40, 498-503, 2010.
- [19] J. M. Khurana and K. Vij, "Nickel nanoparticles: A highly efficient catalyst for one pot synthesis of tetraketones and biscoumarins" *J. Chem. Sci. (Bangalore, India)*, 124, 907-912, 2012.
- [20] S. Khodabakhshi and M. Baghernejad, "Mohr's salt hexahydrate: A novel, cheap and powerful reagent for green synthesis of biscoumarins on water" *J. Chin. Chem. Soc. (Taipei, Taiwan)*, 2013.
- [21] V. Padalkar, K. Phatangare, S. Takale, R. Pisal and A. Chaskar, "Silica supported sodium hydrogen sulfate and Indion 190 resin: An efficient and heterogeneous catalysts for facile synthesis of bis-(4-hydroxycoumarin-3-yl) methanes" *Journal of Saudi Chemical Society*, 2012
- [22] M. M. Heravi, S. Sadjadi, N. M. Haj, H. A. Oskooie and F. F. Bamoharram, "Role of various heteropolyacids in the reaction of 4-hydroxycoumarin, aldehydes and ethylcyanoacetate" *Catal. Commun.*, 10, 1643-1646, 2009
- [23] R. Rezaei and M. R. Sheikhi, "Starch-sulfuric acid as a bio-supported and recyclable solid acid catalyst for rapid synthesis of 4'-benzylidene bis(4-hydroxycoumarin) derivatives" *Res. Chem. Intermed.*, 2013
- [24] R. A. Sheldon, *Fine chemicals*, 102, 104, 2011
- [25] A. Dhakshinamoorthy, M. Alvaro and H. Garcia, "Metal organic frameworks as solid acid catalysts for acetalization of aldehydes with methanol" *Adv. Synth. Catal.*, 352, 3022-3030, 2010.
- [26] A. Takagaki, C. Tagusagawa, S. Hayashi, M. Hara and K. Domen, "Nanosheets as highly active solid acid catalysts for green chemical syntheses" *Energy & Environmental Science*, 3, 82-93, 2010.
- [27] Z. Helwani, M. R. Othman, N. Aziz, J. Kim and W. J. N. Fernando, "Solid heterogeneous catalysts for transesterification of triglycerides with methanol: A review" *Appl. Catal., A*, 363, 1-10, 2009
- [28] R. Martín-Aranda and J. Lejka, "Recent advances in catalysis over mesoporous molecular sieves". *Top. Catal.*, 53, 141-153, 2010
- [29] K. Kandasamy, M. P. Pachamuthu, M. Muthusamy, S. Ganesabaskaran and A. Ramanathan "Synthesis of novel pyrazolylbiscoumarin derivatives using FeTUD-1 as a mesoporous solid acid catalyst" *RSC Adv.*, 3, 25367-25373, 2013